Literature DB >> 17542016

Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz).

J Zh Gao1, M A Hussain, R Motheram, D A B Gray, I H Benedek, W D Fiske, W J Doll, E Sandefer, R C Page, G A Digenis.   

Abstract

Human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble, highly permeable, micronized drug (efavirenz) was investigated. The tablets and capsule, prepared with samarium oxide and neutron activated to produce radioactive samarium-153, were evaluated for their in vivo disintegration and gastrointestinal (GI) transit in healthy subjects under fasted condition. Scintigraphic images were acquired to coincide with blood sampling times to assess the plasma concentration-time profile in relation to in vivo disintegration and GI transit. The mean gastric emptying times were approximately the same for all three formulations. Although in vivo dosage form disintegration was faster for Tablet A as compared to Tablet B and was similar between Tablet A and the capsule, Tablet A showed a slower rate and extent of drug absorption than Tablet B and the capsule. The results of this study eliminated the initial hypothesis that the difference in in vivo performance between the two tablet formulations is due to a different rate of in vivo disintegration and suggest that for this drug the in vivo dissolution rate of the drug from its disintegrated dosage form was a more important factor affecting the rate and extent of drug absorption. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17542016     DOI: 10.1002/jps.20962

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Food Effect in Humans: Predicting the Risk Through In Vitro Dissolution and In Vivo Pharmacokinetic Models.

Authors:  Neil Mathias; Yan Xu; Balvinder Vig; Umesh Kestur; Amy Saari; John Crison; Divyakant Desai; Aditya Vanarase; Munir Hussain
Journal:  AAPS J       Date:  2015-05-02       Impact factor: 4.009

2.  Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.

Authors:  Jason D Robarge; Ingrid F Metzger; Jessica Lu; Nancy Thong; Todd C Skaar; Zeruesenay Desta; Robert R Bies
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes.

Authors:  Sateeshkumar Sathigari; Gurkishan Chadha; Y-H Phillip Lee; Nydeia Wright; Daniel L Parsons; Vijay K Rangari; Oladiran Fasina; R Jayachandra Babu
Journal:  AAPS PharmSciTech       Date:  2009-01-16       Impact factor: 3.246

Review 4.  Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.

Authors:  Iris Usach; Virginia Melis; José-Esteban Peris
Journal:  J Int AIDS Soc       Date:  2013-09-04       Impact factor: 5.396

5.  Influence of the efavirenz micronization on tableting and dissolution.

Authors:  Eduardo Costa Pinto; Flávia Almada do Carmo; Thiago da Silva Honório; Rita de Cássia da Silva Ascenção Barros; Helena Carla Rangel Castro; Carlos Rangel Rodrigues; Valéria Sant'anna Dantas Esteves; Helvécio Vinícius Antunes Rocha; Valeria Pereira de Sousa; Lucio Mendes Cabral
Journal:  Pharmaceutics       Date:  2012-09-12       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.